| Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014 | 1737 | 2014 |
| Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017 | 695 | 2017 |
| Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology T Eschenhagen, T Force, MS Ewer, GW De Keulenaer, TM Suter, ... European journal of heart failure 13 (1), 1-10, 2011 | 523 | 2011 |
| Metformin: taking away the candy for cancer? M Jalving, JA Gietema, JD Lefrandt, S de Jong, AKL Reyners, ROB Gans, ... European journal of cancer 46 (13), 2369-2380, 2010 | 487 | 2010 |
| Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy M Jalving, JJ Koornstra, J Wesseling, HM Boezen, S De Jong, ... Alimentary pharmacology & therapeutics 24 (9), 1341-1348, 2006 | 384 | 2006 |
| TRAIL receptor signalling and modulation: Are we on the right TRAIL? D Mahalingam, E Szegezdi, M Keane, S de Jong, A Samali Cancer treatment reviews 35 (3), 280-288, 2009 | 367 | 2009 |
| Tissue distribution of the death ligand TRAIL and its receptors DC Spierings, EG de Vries, E Vellenga, FA van den Heuvel, JJ Koornstra, ... Journal of Histochemistry & Cytochemistry 52 (6), 821-831, 2004 | 326 | 2004 |
| Heart failure stimulates tumor growth by circulating factors WC Meijers, M Maglione, SJL Bakker, R Oberhuber, LM Kieneker, ... Circulation 138 (7), 678-691, 2018 | 310 | 2018 |
| Preclinical characterisation of 111In‐DTPA‐trastuzumab MN Lub‐de Hooge, JGW Kosterink, PJ Perik, H Nijnuis, L Tran, J Bart, ... British journal of pharmacology 143 (1), 99-106, 2004 | 304 | 2004 |
| The clinical trail of TRAIL EW Duiker, CH Mom, S De Jong, PHB Willemse, JA Gietema, ... European journal of cancer 42 (14), 2233-2240, 2006 | 253 | 2006 |
| Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer R Koster, A Di Pietro, H Timmer-Bosscha, JH Gibcus, A Van Den Berg, ... The Journal of clinical investigation 120 (10), 3594-3605, 2010 | 247 | 2010 |
| Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer B Pennarun, A Meijer, EGE de Vries, JH Kleibeuker, F Kruyt, S de Jong Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1805 (2), 123-140, 2010 | 245 | 2010 |
| Fas receptor‐mediated apoptosis: a clinical application? T Timmer, EGE de Vries, S de Jong The Journal of Pathology: A Journal of the Pathological Society of Great …, 2002 | 230 | 2002 |
| Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic DJA De Groot, EGE De Vries, HJM Groen, S De Jong Critical reviews in oncology/hematology 61 (1), 52-69, 2007 | 229 | 2007 |
| Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family K Azijli, B Weyhenmeyer, GJ Peters, S De Jong, FAE Kruyt Cell Death & Differentiation 20 (7), 858-868, 2013 | 227 | 2013 |
| Survival-related profile, pathways, and transcription factors in ovarian cancer APG Crijns, RSN Fehrmann, S de Jong, F Gerbens, GJ Meersma, HG Klip, ... PLoS medicine 6 (2), e1000024, 2009 | 218 | 2009 |
| Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy CMM Van Geelen, EGE de Vries, S de Jong Drug resistance updates 7 (6), 345-358, 2004 | 213 | 2004 |
| Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line S de Jong, JG Zijlstra, EGE de Vries, NH Mulder Cancer research 50 (2), 304-309, 1990 | 207 | 1990 |
| The insulin‐like growth factor system and sarcomas B Rikhof, S de Jong, AJH Suurmeijer, C Meijer, WTA van der Graaf The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009 | 190 | 2009 |
| Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors DCJ Spierings, EGE de Vries, W Timens, HJM Groen, HM Boezen, ... Clinical cancer research 9 (9), 3397-3405, 2003 | 190 | 2003 |
Elisabeth de VriesProfessor of Medical Oncology, University Medical Center Groningen, Groningen, the NetherlandsDirección de correo verificada de umcg.nl
